EURO-SEQUENCES · Project

Programmable Plastics: Writing Digital Information Into Polymer Chains for Smarter Materials

manufacturingPrototypeTRL 3Thin data (2/5)

becergroup.sems.qmul.ac.uk

Imagine if you could write a message into the very structure of a plastic material — letter by letter — the same way nature writes instructions into DNA. That's what this project worked on: building synthetic polymers where every building block is placed in a precise order, giving the material programmable properties. The team developed new chemical methods to "write" information onto polymer chains, plus tools to "read" those sequences back. The long-term vision is plastics that can store data, deliver drugs precisely, or act as tiny catalysts — all because their molecular code was designed on purpose.

By the numbers

consortium partners across the network

countries represented (BE, DE, FR, NL, UK)

industry partners in the consortium

total project deliverables

patent application planned on new technology

academic partners in the network

The business problem

What needed solving

Traditional plastics are mass-produced with random molecular structures, giving manufacturers limited control over material properties at the molecular level. When companies need materials with ultra-specific functions — precise drug delivery, molecular-scale data storage, or tailored catalytic behaviour — off-the-shelf polymers fall short. The gap between what biology can do with precisely sequenced molecules (like DNA and proteins) and what industry can manufacture synthetically remains wide.

The solution

What was built

The project developed new chemical methods for writing precise monomer sequences onto synthetic polymer chains, along with analytical techniques for reading and characterising those sequences. They also investigated how these sequence-controlled polymers fold and self-assemble. At least one patent application was filed on a new technology developed during the project, out of 8 total deliverables.

Audience

Who needs this

Specialty polymer and advanced materials manufacturersMolecular data storage R&D teams at tech companiesDrug delivery and nanomedicine developersCatalysis companies seeking programmable catalyst supportsCoatings and functional films producers needing tunable surface properties

Business applications

Who can put this to work

Advanced Materials & Specialty Chemicals

enterprise

Target: Specialty polymer manufacturers or chemical companies developing next-generation plastics

If you are a specialty chemicals company struggling to create plastics with precisely tuned properties — this project developed chemical methods for writing exact molecular sequences into synthetic polymers. The consortium of 9 partners across 5 countries built techniques that let you control polymer chain structure at the monomer level, opening the door to materials with programmable behaviour for catalysis, coatings, or functional films.

Data Storage & Electronics

enterprise

Target: Companies exploring molecular-scale or DNA-based data storage solutions

If you are a data storage company looking beyond silicon for ultra-dense archival storage — this project explored molecular data storage using sequence-controlled polymers. The team developed methods to encode information at the molecular level and analytical techniques to read it back, offering a potential path to storage media that could outlast magnetic or optical formats by decades.

Pharmaceutical & Nanomedicine

mid-size

Target: Drug delivery companies or biotech firms working on precision therapeutics

If you are a pharmaceutical company trying to improve targeted drug delivery — this project investigated how sequence-controlled polymers fold and self-assemble, much like proteins do. Understanding this structure-to-function relationship could enable synthetic polymer carriers that deliver drugs to specific tissues, with the precision currently only seen in biological molecules.

Frequently asked

Quick answers

What would it cost to license or access this technology?

The project listed at least one patent application as a deliverable, suggesting protectable IP was generated. Licensing terms would need to be negotiated directly with CNRS (the coordinator) or the specific partner holding the patent. As a publicly funded MSCA training network, some research outputs may be available through academic collaboration agreements.

Can this scale to industrial production?

Based on available project data, the focus was on developing fundamental chemical methods for sequence-controlled polymer synthesis. The objective explicitly states that 'fundamental and applied research is still mandatory' in this field. Industrial-scale production methods were not the primary goal of this training network.

What intellectual property came out of this project?

The project explicitly planned for at least one patent application on a new technology developed during the research. With 7 academic partners and 2 companies in the consortium, IP ownership likely follows the Horizon 2020 grant agreement rules, where each partner owns the IP they generate. Contact CNRS for specifics on patent status and licensing.

How mature is this technology — could we use it today?

This was a Marie Skłodowska-Curie training network (2015-2018) focused on PhD training and fundamental research. The objective describes the field as 'young' with mandatory fundamental research still needed. Real-world applications in data storage, catalysis, and nanomedicine remain at an early research stage.

Who were the industry partners and what did they contribute?

The consortium included 2 industry partners out of 9 total, with 1 SME. The industry ratio was 22%. These companies brought complementary expertise alongside 6 universities and 1 research organisation across 5 countries (Belgium, Germany, France, Netherlands, UK).

What specific outputs could a business use right now?

The project produced 8 deliverables including new chemical synthesis methods, analytical characterisation techniques for polymer sequencing, and at least one patent application. However, these are primarily research tools and methods rather than market-ready products. A company would need further development and engineering to turn these into commercial offerings.

Are there regulatory hurdles for these materials?

Based on available project data, regulatory pathways were not addressed directly. Any nanomedicine applications would face standard pharmaceutical approval processes. For data storage or industrial catalysis applications, materials safety and REACH compliance in the EU would apply. The project focused on fundamental science rather than regulatory preparation.

Consortium

Who built it

The EURO-SEQUENCES consortium brought together 9 partners from 5 countries (Belgium, Germany, France, Netherlands, UK), coordinated by CNRS — France's largest public research organisation. The network was heavily academic with 6 universities and 1 research body, plus 2 industry partners (including 1 SME), giving an industry ratio of 22%. For a business looking to access this technology, the low industry participation signals this is still deep in the research phase. The multi-country, multi-discipline setup — spanning organic chemistry, polymer synthesis, supramolecular chemistry, and materials science — means the knowledge base is broad but the path to commercialisation would require significant additional investment and industrial partnerships.

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSCoordinator · FR
IONERA TECHNOLOGIES GMBHparticipant · DE
THE UNIVERSITY OF MANCHESTERparticipant · UK
THE UNIVERSITY OF READINGparticipant · UK
UNIVERSITEIT GENTparticipant · BE
STELLANTIS AUTO SASparticipant · FR
HUMBOLDT-UNIVERSITAET ZU BERLINparticipant · DE
QUEEN MARY UNIVERSITY OF LONDONparticipant · UK
TECHNISCHE UNIVERSITEIT EINDHOVENparticipant · NL

How to reach the team

CNRS (Centre National de la Recherche Scientifique), France — reach out through their technology transfer office (CNRS Innovation) for licensing inquiries

Order a report on this consortium See CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS profile →

Next steps

Talk to the team behind this work.

Want to explore whether sequence-controlled polymer technology fits your R&D pipeline? SciTransfer can connect you directly with the research team and help assess commercial fit.

Order a report on this topic More in Manufacturing & Industry 4.0